Evidence map›Paper›PMID 36812492›Full record

ArticleJournal of medicinal chemistry2023

Optimization of 2,3-Dihydroquinazolinone-3-carboxamides as Antimalarials Targeting PfATP4.

Trent D Ashton, Madeline G Dans, Paola Favuzza, Anna Ngo, Adele M Lehane, Xinxin Zhang, Deyun Qiu, Bikash Chandra Maity, Nirupam De, Kyra A Schindler and 13 more

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Antimalarial drug discovery: progress and approaches.Nature reviews. Drug discovery · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Trent D AshtonThe Walter and Eliza Hall Institute of Medical Research, Parkville 3052, Australia.ORCID 0000-0002-6707-6064
Madeline G DansThe Walter and Eliza Hall Institute of Medical Research, Parkville 3052, Australia.
Paola FavuzzaThe Walter and Eliza Hall Institute of Medical Research, Parkville 3052, Australia.
Anna NgoThe Walter and Eliza Hall Institute of Medical Research, Parkville 3052, Australia.
Adele M LehaneResearch School of Biology, Australian National University, Canberra 2601, Australia.ORCID 0000-0002-0050-9101
Xinxin ZhangResearch School of Biology, Australian National University, Canberra 2601, Australia.
Deyun QiuResearch School of Biology, Australian National University, Canberra 2601, Australia.
Bikash Chandra MaityTCG Lifesciences Pvt. Ltd., Saltlake Sec-V, Kolkata 700091, West Bengal, India.
Nirupam DeTCG Lifesciences Pvt. Ltd., Saltlake Sec-V, Kolkata 700091, West Bengal, India.
Kyra A SchindlerDepartment of Microbiology & Immunology, Columbia University, Irving Medical Center, New York, New York 10032, United States.
Tomas YeoDepartment of Microbiology & Immunology, Columbia University, Irving Medical Center, New York, New York 10032, United States.
Heekuk ParkDepartment of Microbiology & Immunology, Columbia University, Irving Medical Center, New York, New York 10032, United States.
Anne-Catrin UhlemannDepartment of Microbiology & Immunology, Columbia University, Irving Medical Center, New York, New York 10032, United States.ORCID 0000-0002-9798-4768
Alisje ChurchyardDepartment of Life Sciences, Imperial College London, South Kensington SW7 2AZ U.K.
Jake BaumDepartment of Life Sciences, Imperial College London, South Kensington SW7 2AZ U.K.
David A FidockDepartment of Microbiology & Immunology, Columbia University, Irving Medical Center, New York, New York 10032, United States.
Kate E JarmanThe Walter and Eliza Hall Institute of Medical Research, Parkville 3052, Australia.
Kym N LowesThe Walter and Eliza Hall Institute of Medical Research, Parkville 3052, Australia.
Delphine BaudMedicines for Malaria Venture, ICC, Route de Pré-Bois 20, 1215 Geneva, Switzerland.
Stephen BrandMedicines for Malaria Venture, ICC, Route de Pré-Bois 20, 1215 Geneva, Switzerland.
Paul F JacksonGlobal Public Health, Janssen R&D LLC, La Jolla, California 92121, United States.
Alan F CowmanThe Walter and Eliza Hall Institute of Medical Research, Parkville 3052, Australia.
Brad E SleebsThe Walter and Eliza Hall Institute of Medical Research, Parkville 3052, Australia.ORCID 0000-0001-9117-1048

Funding

Wellcome Trust
6 · The paper itself

Abstract

There is an urgent need to populate the antimalarial clinical portfolio with new candidates because of resistance against frontline antimalarials. To discover new antimalarial chemotypes, we performed a high-throughput screen of the Janssen Jumpstarter library against the

Indexed as

AntimalarialsMalariaMalaria, FalciparumAnimalsHomeostasisMicePlasmodium falciparumAntimalarials

Identifiers

PMID36812492
PMCPMC10009754

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.